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Abstract
Rates of lung cancer in American men have greatly
exceeded those in Japanese men for several decades
despite the higher smoking prevalence in Japanese men.
It is not known whether the relative risk of lung cancer
associated with cigarette smoking is lower in Japanese
men than American men and whether these risks vary by
the amount and duration of smoking. To estimate
smoking-specific relative risks for lung cancer in men, a
multicentric case-control study was carried out in New
York City, Washington, DC, and Nagoya, Japan from
1992 to 1998. A total of 371 cases and 373 age-matched
controls were interviewed in United States hospitals and
410 cases and 252 hospital controls in Japanese hospitals;
411 Japanese age-matched healthy controls were also
randomly selected from electoral rolls. The odds ratio
(OR) for lung cancer in current United States smokers
relative to nonsmokers was 40.4 [95% confidence interval
(CI)  21.8–79.6], which was >10 times higher than the
OR of 3.5 for current smokers in Japanese relative to
hospital controls (95% CI  1.6–7.5) and six times
higher than in Japanese relative to community controls
(OR  6.3; 95% CI  3.7–10.9). There were no
substantial differences in the mean number of years of
smoking or average daily number of cigarettes smoked
between United States and Japanese cases or between
United States and Japanese controls, but American cases
began smoking on average 2.5 years earlier than
Japanese cases. The risk of lung cancer associated with
cigarette smoking was substantially higher in United
States than in Japanese males, consistent with population-
based statistics on smoking prevalence and lung cancer
incidence. Possible explanations for this difference in risk
include a more toxic cigarette formulation of American
manufactured cigarettes as evidenced by higher
concentrations of tobacco-specific nitrosamines in both
tobacco and mainstream smoke, the much wider use of
activated charcoal in the filters of Japanese than in
American cigarettes, as well as documented differences in
genetic susceptibility and lifestyle factors other than
smoking.
Introduction
Since the 1950s, lung cancer rates in American men have
greatly exceeded those in Japanese men, despite a much lower
prevalence of smoking in the United States The mortality rates
of lung cancer were two to three times higher in the United
States during this period, although both countries experienced
a substantial increase from 1955 to 1985 (1, 2). Incidence trends
were similar to mortality: the 1988–1992 lung cancer incidence
in white males in the United States Surveillance Epidemiology
and End Results program of the National Cancer Institute areas
was 61.3 per 100,000 compared with 39.6 for males in Miyagi
Prefecture (3). During the same 30-year period, there was a
decline in the prevalence of smoking from 54% in 1955 to 33%
in 1985 in United States men, whereas the percentage of Jap-
anese men who smoked increased from 76% in 1955 to a peak
of 82% in 1965 before declining to 60% in 1992 (4, 5).
The rates of lung cancer in Japanese migrants and their
offspring in the United States are similar to United States-born
whites, which strongly suggests that most of the international
variation in lung cancer rates is not attributable to ethnic dif-
ferences in susceptibility (6). In a comparison of several pro-
spective studies of lung cancer mortality rates, smoking-
specific rates were consistently lower in Japanese than in
British, Norwegian, Swedish, or American smokers (7, 8).
Although there are other risk factors for lung cancer including
exogenous factors such as diet (9, 10), occupation (11), and
inborn differences in metabolizing enzymes (12), cigarette
smoking causes 90% of cases (8). Therefore, attempts to
explain this anomaly must begin with a comparison of smok-
ing-specific factors such as the duration of smoking habit, cpd,4
or age at onset of smoking.
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This study took advantage of long-standing collaborations
between the American Health Foundation and Japanese re-
searchers. In 1977, Wynder and Hirayama (1) summarized the
trends and differences in United States and Japanese cancer
rates in relation to lifestyle characteristics. Subsequently, they
found that lung cancer rates were rapidly increasing among
Japanese men as a consequence of increased numbers of heavy
cigarette smokers (2). The United States-Japan lung cancer
anomaly has persisted in more recent comparisons (13). Be-
cause these ecological comparisons of population data cannot
directly establish the risk of smoking, we conducted a multi-
centric case-control study in the United States and Japan to
compare smoking behaviors as risk factors in both countries.
Materials and Methods
Participating Centers. Study subjects were interviewed in a
case-control study conducted simultaneously in large urban
centers in the United States and Japan. Eight Japanese hospitals
in Nagoya and 10 United States hospitals participated (see
“Acknowledgments”). The majority of United States patients
(80%) were enrolled in hospital cancer centers in New York
City (Memorial Sloan-Kettering Cancer Center, Columbia-
Presbyterian Medical Center, Tisch Hospital-New York Uni-
versity Medical Center, and Long Island Jewish Medical Cen-
ter) and Washington, DC (George Washington University
Medical Center). Japanese cancer patients were recruited at
Aichi Cancer Center in Nagoya (44%), National Nagoya Hos-
pital (24%), First Red Cross Hospital (17%), Aichi Prefectural
Hospital, and several smaller hospitals in Aichi Prefecture
(15%).
Eligibility. Cases were patients between the ages of 20 and 81
years newly diagnosed with primary lung cancer within 1 year
of the interview date and who had no previous history of
another tobacco-related cancer. All of the cases were histolog-
ically or cytologically confirmed through hospital pathology
reports or discharge summaries. United States lung cancer cases
were patients admitted to participating hospitals between
March 1992 and February 1997; Japanese cases were enrolled
between June 1993 and May 1998. Hospital controls were
patients ages 20–81 years admitted for a nontobacco related
condition and having no history of the following tobacco re-
lated diseases: cancer of the esophagus, larynx, oral cavity,
nasal sinus, pancreas, liver, kidney, or bladder. Patients hospi-
talized for other tobacco-related cardiovascular conditions (i.e.,
myocardial infarction, stroke, or coronary artery disease) and
respiratory disorders (i.e., emphysema, chronic bronchitis, or
chronic obstructive pulmonary disease) were also excluded as
hospital controls. Hospital controls in both countries were fre-
quency matched on age (5 years), hospital, and date of
interview (initially 2 months, extended in September 1995
to 4 months in Japan because of the requirement of obtaining
individual physician consents). Hospital controls in both coun-
tries included large percentages of patients with digestive, gen-
itourinary, and musculoskeletal diseases, and injury or poison-
ing. However, a higher percentage of United States controls
were admitted for neoplasms (29.0% versus 1.2% in Japan), of
which 38.9% were cases of malignant neoplasm of prostate, and
25.9% were cases of leukemia and lymphoma; 56.3% of Japan
hospital controls were diagnosed with digestive and genitouri-
nary diseases compared with 32.1% of United States hospital
controls.
Hospital controls were included in the United States com-
ponent of the study because we previously showed no differ-
ences in smoking prevalence between hospital and community-
based controls (14). Because it had not been determined
previously whether smoking prevalence was similar in Japa-
nese hospital patients and community members, the Japanese
study design included both hospital and community-based con-
trols. Controls were frequency matched by age (5 years), date
of interview (2 months; 4 months after September 1995),
and neighborhood of residence to cases. Community controls
were chosen from residents who lived in the same or neigh-
boring district of the hospital in which matching cases were
chosen in a random selection process from a list of names with
corresponding addresses and dates of birth, kept as part of the
electoral records system in Nagoya and Okazaki City. The
United States portion of the study comprised 371 white male
cases and 373 white male hospital controls. The total number of
male Japanese subjects available for analysis included 410 lung
cancer cases, 252 hospital controls, and 411 community con-
trols. The overall response rate among United States patients
was 82.8% of those approached and was nearly identical among
cases and controls. Response rates in Japanese cases and con-
trols were similar and also exceeded 80%.
Questionnaires and Interview Procedures. The Japanese
version of the questionnaire was developed by translating the
English version and then back-translating it into English by a
different translator to insure comparability. Trained interview-
ers were given the same instructions in both countries. To
assure procedural uniformity in the two countries, three of the
Japanese investigators, who are all fluent in English, received
intensive training in New York, whereas one of the United
States investigators (S. D. S.) made frequent visits to the Jap-
anese sites. The Japanese questionnaire was printed in bilingual
form to facilitate data entry by the American keypunchers. All
of the subjects signed a consent form, which was approved by
the Institutional Review Boards of the collaborating institu-
tions. The questionnaire included detailed items on smoking
history such as age at onset, smoking status, years and amount,
cigarette brand, history, and years since quitting.
Smoking Categories. Subjects were classified as nonsmokers
(never smoked regularly; i.e., at least once a day for 1 year),
current smokers (smoked within the past year), or ex-smokers
(did not smoke within the past year). Persons who smoked
cigars or pipes only were excluded from the analyses except for
the descriptions of mean age and years of education. Among
United States men, “cigar/pipe only” smokers made up 5.4%
and 0.85% of cases and controls, respectively; there were no
Japanese subjects who reported smoking either cigars or pipes.
Statistical Methods. OR and 95% CI were calculated by lo-
gistic regression, and adjusted for confounding variables such
as age at diagnosis, education (three categories: 12, 12, 12
years), and hospital (for analyses using hospital controls).
Dummy variables were introduced to code categories of smok-
ing status (non-, current, or ex-smoker), total years of smoking
(40 or 41 years), average number of cpd (20, 20–29,30
cpd), age at onset of smoking (0–14, 15–17, 18–20, 20 years
old), and number of years since quit smoking (1–9, 10–15, 16
years). Wald’s 2 statistic was used to test statistical signifi-
cance against the null hypothesis of no association, and 95%
CIs were obtained. Differences in mean values were tested for
significance with Student’s t. The 2 test for trend was con-
ducted by the Mantel-Haenszel extension method with data
stratified into age groups by decade.
Results
Table 1 compares the distributions of age and education in
cases and controls in the United States and Japanese study
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populations. As expected, cases in both countries were less
educated than controls, but the matching insured that the ages
were similar between hospital cases and controls. Japanese
community controls were somewhat younger than their corre-
sponding cases.
Table 2 shows the smoking prevalence in the two countries
and corresponding ORs for lung cancer. In controls, the per-
centage of current smokers was greater in Japan than in the
United States. In both countries smoking was strongly related to
the risk of lung cancer, and the risk for former smokers was
about one-third that for current smokers. However, the strength
of the association between lung cancer and smoking differed
substantially between the two countries. The OR for lung can-
cer among current smokers relative to nonsmokers in the United
States was 40.4 (95% CI  21.8–79.6), which was 10 times
larger than that in Japan when using hospital controls (OR 
3.5; 95% CI 1.6–7.5) and more than six times as large as that
in Japan when using community controls (OR 6.3; 95% CI
3.7–10.9). Similarly, the ORs for ex-smokers were five to eight
times as great in the United States as in Japan, respectively. The
small number of nonsmokers among cases in both countries
resulted in wide CIs; however, the 95% CI for lung cancer risks
for United States and Japanese subjects do not overlap.
We examined whether specific smoking variables such as
smoking duration, cpd, or age at onset accounted for the lower
risk in Japan (Table 3). For all three of the variables, the
magnitudes of the ORs were much greater in the United States
subjects than in the Japanese subjects. There were no signifi-
cant differences in mean years of smoking between United
States and Japanese cases or between the United States controls
and either set of Japanese controls. In both countries there was
a strong dose-response relationship with years of smoking, but
within each duration stratum the adjusted American ORs were
from 5 to 12 times as high as the Japanese ORs. For example,
the adjusted OR for lung cancer in United States subjects who
had smoked for 40 years was 57.8 (95% CI  27.4–132),
whereas for Japanese subjects it was 7.4 (95% CI  2.9–19.4)
using hospital controls and 8.3 (95% CI  4.5–15.4) using
community controls.
Also as expected, there was a strong dose-response rela-
tionship between lung cancer risk and cpd in both United States
and Japanese subjects. There were no significant differences in
the average number of cpd between United States and Japanese
controls. The adjusted ORs in the United States study popula-
tion ranged from 4 to 15 times that of the Japanese within the
same cpd stratum. For example, for subjects who currently
smoked 20–29 cpd, the OR in United States subjects was 53.4
(95% CI  23.1–135), whereas in Japanese subjects it was 3.5
(95% CI 1.5–8.4) when using hospital controls and 4.3 (95%
CI  2.4–7.6) when using community controls.
Table 3 also shows that the average age of smoking onset
was 2.5 years later for Japanese cases than American cases
(P  0.001) and 2.4 to 2.7 years later for Japanese compared
with American controls (P  0.01). Whereas one-fifth of the
currently smoking controls in the United States had started
smoking before age 15, there were almost no Japanese who
reported starting smoking so young. Statistically significant
trends of decreasing lung cancer risk with later age of onset of
smoking were observed in both countries (P  0.01 in United
States and P 0.001 in Japan). The estimated effect of starting
to smoke at a later age was more apparent using community
controls as a reference than hospital controls.











controls (n  411)
Age
39 1.6 1.3 1.7 2.4 1.5
40–49 5.7 8.6 10.0 15.5 10.0
50–59 20.8 18.5 24.2 34.1 22.1
60–69 42.9 42.4 42.2 35.7 41.1
70 29.1 29.2 22.0 12.3 25.3
Total 100 100 100 100 100
Education level in years
12 17.6 11.5 52.8 43.0 42.4
12 27.6 22.8 22.6 26.3 19.8
12 54.9 65.7 24.6 30.7 37.8
Total 100 100 100 100 100
a Distribution is by percentage.








OR (95% CI)a % Cases(n  410)
% Hospital




OR (95% CI) (HCa/CCb)
Nonsmokers 4.3 41.0 1 4.6 11.5 17.0 1
Ex-smokers 55.8 48.5 10.5 (6.2–19.0) 26.1 42.9 44.0 1.3 (0.6–2.9)/2.2 (1.3–4.0)
Current smokers 39.9 10.5 40.4 (21.8–79.6) 69.3 45.6 38.9 3.5 (1.6–7.5)/6.3 (3.7–10.9)
Total 100 100 100 100 100
a HC, hospital controls. Reference group is nonsmokers; adjusted for age, education, and hospital.
b CC, community controls. Reference group is nonsmokers; adjusted for age and education.
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Table 4 displays the pattern of the reduction in lung cancer
risk in ex-smokers according to years since quitting, relative to
current smokers. Among United States subjects, the risk was
reduced as much as 50% for those who had quit within the last
10 years, whereas among Japanese former smokers, the corre-
sponding reduction was only 10–20%. The relative risk esti-
mates were examined by the two most common histological
types of lung cancer: AC and SCC (Table 5). OR estimates for
SCC are not shown for the United States study population,
because there were no SCC cases among nonsmokers and only
32 among current smokers. ORs for AC in the United States
population and for both histological types in Japan increased
both with duration and with cpd. ORs for AC in the United
States population were all significantly 1 and were greater
than those in Japan. Among Japanese current smokers, a steeper
increase in ORs was observed for SCC compared with ORs for
AC, and ORs calculated from community controls were larger
than those obtained by using hospital controls.
Discussion
The risk of lung cancer in the United States study population
was at least 10 times higher than in Japanese despite the higher
percentage of smokers among the Japanese. These findings are
consistent with ecological data on smoking and lung cancer
rates in the United States and Japan described previously (13).
Our results are also consistent with comparisons of studies of
lung cancer risk associated with ever-smoking (4, 15–23). For
example, Sobue et al. (17) showed that the relative risk for
Japanese smokers versus nonsmokers had risen over time but
was still less than the risks for Western European smokers. The
risks for lung cancer in current cigarette smokers ranged from
2.1 to 4.4 in Japanese studies as compared with 9 to 15.8 in
United States and Western European studies (15, 18, 19).
An important difference between United States and Japa-
nese smokers was the lower average age at onset of smoking in
American men (15 years), which was associated with an
elevated risk of lung cancer. Almost no Japanese smokers
began smoking before the age of 15. Nevertheless, earlier age
of smoking onset was also a risk factor in Japanese men as
shown by the lower ORs associated with smoking onset at age
of 18 or older compared with an earlier age at onset of smoking
(between 15 and 17 years of age). Sobue et al. (17) have noted
that smoking has been illegal in Japan for persons under age 20
since 1900. However, this prohibition is clearly flouted by
younger Japanese, according to surveys in Japanese high
schools that showed rapidly increasing smoking rates during
the 1980s (24).
Although some epidemiological studies have suggested
that age at onset of smoking is an independent risk factor for
lung cancer (25), this relationship remains controversial, since
early age at onset of smoking is associated with heavy subse-
quent cigarette consumption (26). A recent study also showed
that the effect of age at onset of smoking is not strong enough
to explain the causal relationship between smoking and damage
in lung tissues among current smokers, but was a significant
Table 3 Lung cancer risk in current smokers in relation to smoking duration, cpd, and age at onset of smoking habit
United States Japan




Controls OR (95% CI) (HC; CC)
a
n 148 39 284 115 160
Smoking duration (yr) %
40 38.5 56.4 25.2 (11.9–61.0)b 40.5 71.3 45.0 2.2 (1.1–5.2); 4.8 (2.6–8.9)c
40 61.5 43.6 57.8 (27.4–131.9)b 59.5 28.7 55.0 7.4 (2.9–19.4); 8.3 (4.5–15.4)c
Mean (SD) 42.6 (10.8) 38.7 (12.3) 41.6 (9.8) 35.4 (9.8) 40.6 (10.3)
cpd %
20 10.8 38.5 10.9 (4.4–28.0)b 16.8 29.8 30.6 1.6 (0.7–3.9); 2.6 (1.4–4.9)c
20–29 35.1 28.2 53.4 (23.1–135.2)b 35.0 34.2 41.3 3.5 (1.5–8.4); 4.3 (2.4–7.6)c
30 54.1 33.3 73.3 (32.5–181.6)b 48.2 36.0 28.1 6.2 (2.6–15.0); 9.3 (5.2–16.7)c,d
Mean (SD) 30.6 (15.5) 22.9 (16.4) 29.5 (15) 25 (14.8) 22.7 (12.8)
Age at onset of smoking (yr) %
14 30.4 20.5 1.2 (0.4–3.4)e 0.7 0.0 0.0 (f)
15–17 38.5 33.3 1 (reference)e 21.1 11.3 15.6 1 (reference)g
18–20 18.2 25.6 0.6 (0.2–1.7)e 61.6 68.7 60.0 0.2 (0.1–0.6); 0.8 (0.5–1.3)g
20 12.8 20.5 0.5 (0.2–1.4)e 16.6 20.0 24.4 0.2 (0.1–0.8); 0.5 (0.3–0.9)g,h
Mean (SD) 16.8 (5.8) 17.8 (5.0) 19.3 (2.9) 20.2 (4.7) 20.5 (5.8)
a HC, hospital controls; CC, community controls.
b Adjusted for age, education, and hospital; reference group is nonsmokers.
c Adjusted for age and education; reference group is nonsmokers.
d P  0.001, test for linear trend.
e Adjusted for age, education and hospital; reference group is 15–17 yrs.
f ORs were not computed because no current smokers started smoking before the age of 15 in Japanese controls.
g Adjusted for age and education; reference group is 15–17 yrs.
h P  0.01, test for linear trend.
Table 4 Adjusted ORs for lung cancer comparing ex-smokers with current











OR (95% CI)b OR (95% CI)a OR (95% CI)b
Current Smokers 1 1 1
Ex-smokers
1–4 0.5 (0.3–1.0) 0.9 (0.3–2.9) 0.9 (0.5–1.7)
5–9 0.5 (0.2–0.9) 0.8 (0.3–1.8) 0.8 (0.5–1.4)
10–15 0.4 (0.2–0.8) 0.2 (0.1–0.5) 0.2 (0.1–0.4)
16 0.1 (0.1–0.2)c 0.2 (0.1–0.4)c 0.2 (0.1–0.30)c
a Reference group is current-smokers; adjusted for age, education, and hospital.
b Reference group is current-smokers; adjusted for age and education.
c P  0.001, test for linear trend.
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factor among ex-smokers (27). Hence, although it is possible
that the higher risk of lung cancer in the United States might
partly result from earlier age at onset of smoking among current
smokers, it is unlikely to account for the large difference in OR
between United States and Japan.
Numerous studies have found that lung cancer risk de-
creases with increasing years since quitting in the United States
(8, 28, 29) and Japan (17, 30). In the present study, it was
observed that American former smokers experienced a more
dramatic reduction in lung cancer risk during the first decade
after cessation than the Japanese ex-smokers did. After 16 years
of cessation, lung cancer risks for ex-smokers in both countries
were slightly lower for the United States group. Given the
higher overall risk among United States current cigarette smok-
ers, this additionally emphasizes the importance of smoking
cessation as an essential risk reduction step for all smokers.
The dose-response for SCC was considerably steeper than
for AC in the Japanese population whether duration or cpd was
the dosage variable (Table 5). This disparity in histology-
specific risks is consistent with reports from case-control stud-
ies reported from both the United States and Japan over the past
2 decades (Refs. 17, 31, 32; Table 6). The risk for SCC in the
United States group would undoubtedly have been much
greater than for AC had there been sufficient cases to permit
computation; however, the steady decline in the prevalence of
current smokers among American men in the lung cancer age
group along with the continuing clinical shift from SCC to AC
(33) has greatly reduced the available number of cases with
SCC that are either current smokers or nonsmokers. The rela-
tive proportions of SCC and AC were similar in both countries.
There are several possible explanations for higher smok-
ing-related risks in the United States than in Japan, beginning
with the observation that mainstream smoke from American
cigarettes may contain higher concentrations of toxic and car-
cinogenic compounds than that of Japanese cigarettes (34).
Measurements made in our laboratories have found that the
leading brands of United States cigarettes deliver 35% more
benzo(a)pyrene and 170% more NNK than do the leading
Japanese brands when measured in mainstream smoke under
standardized experimental conditions (i.e., the United States
Federal Trade Commission machine-smoking protocol; Ref.
35) despite similar deliveries of nicotine (34). This marked
difference in delivery of two major classes of lung carcinogens
is probably partly attributable to differences in the tobacco













Smoking duration in years
Nonsmokers 1 1 1 1 1
40 15.1 (5.2–43.9) 1.1 (0.4–2.8) 2.6 (1.3–5.4) 6.3 (1.2–33.4) 13.1 (2.9–58.6)
40 34.7 (14.1–85.5) 3.9 (1.3–11.5) 4.1 (1.9–8.6) 19.3 (3.8–99.0) 22.8 (5.2–99.4)
cpd
Nonsmokers 1 1 1 1 1
20 7.0 (2.2–22.4) 0.6 (0.2–1.8) 1.2 (0.5–29) 7.4 (1.3–42.2) 10.2 (2.2–46.7)
20–29 37.3 (12.7–109.7) 2.2 (0.8–5.9) 2.9 (1.4–5.9) 13.7 (2.5–76.2) 14.1 (3.2–62.1)
30 54.6 (18.8–158.4) 3.3 (1.2–8.8) 5.5 (2.7–11.3) 31.8 (5.4–185.8) 35.7 (8.1–156.5)
a ORs for SCC were highly unstable in the United States study population; there were no cases observed among nonsmokers and only 32 among current smokers.
b Reference group is current-smokers; adjusted for age, education, and hospital.
c Reference group is current-smokers; adjusted for age and education.
Table 6 Comparison of ORs for lung cancer in recent Japanese and Western studies
SCCa ACa All typesa
Ex Current Ex Current Ex Current
Japan
Present studyb 5.7 18.5 1.5 3.2 2.2 6.3
Nakamura22 3.7 6.0 1.7 2.8
Ohno20 2.5 4.1
Gao4 3.6 6.6
Shimizu21 12.8c 1.5c 3.1c,d
Sobue17 13.1 18.1 1.5 1.9 2.8 4.1
Western Europe
Lubin18 8.4–23.0 20.9 1.8–3.5 3.5
United States
Present Study e e 6.4 25.6 10.5 40.4
Thun23 f 19.2
a Reference group is nonsmokers.
b Risks estimated using community controls.
c Ex-smokers were included with current smokers.
d Estimated from published data.
e Could not be estimated because of the lack of nonsmoking cases.
f Not reported because of too few nonsmoking cases.
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blends used in the manufacture of American and Japanese
cigarettes and partly to the much wider use of charcoal filters in
Japanese cigarettes. Samples of American blended tobacco
contain 2.6 times the concentration of NNK and 1.4 times the
concentration of nitrate as do samples of Japanese blended
tobacco (36). Furthermore, for the past two decades, more than
two-thirds of cigarettes purchased in Japan have had charcoal
filters, compared with 1% of cigarettes purchased in the
United States (34). Charcoal filter tips selectively remove cer-
tain gaseous/volatile compounds (e.g., hydrogen cyanide, form-
aldehyde, acetaldehyde, and acrolein) in mainstream smoke
that are known inhibitors of lung clearance; charcoal filters also
have a tendency to selectively retain benzene and toluene (37,
38). Doses of carcinogens “presented” to Japanese and Amer-
ican smokers may also differ because of differences in smoking
topography (inhalation, puff volume, and so forth). We have
found that American smokers of low- and medium-yield ciga-
rettes (1.2 mg nicotine) inhale more than twice as much
nicotine, “tar,” and NNK as predicted by the United States
Federal Trade Commission protocol (35); such measurements
have yet to be made for Japanese smokers.
Both genetic and lifestyle factors may modify smoking-
related lung cancer risk. A higher prevalence has been reported
in Japanese of genetic polymorphisms in some P450 enzymes
that catalyze activation of carcinogenic polycyclic aromatic
hydrocarbons such as those found in cigarette smoke (39, 40).
Tyndale et al. (41) recently found the prevalence of the (pro-
tective) *2 and *4 null alleles of CYP2A6 to be 21.2% in
Japanese compared with 2.6% in Caucasians; this enzyme is
one of several that metabolically activate N-alkylnitrosamines
such as NNK (42). Polymorphisms such as these may be
associated with as much as a 2-fold risk of lung cancer in both
white and Japanese populations (12), but many other factors
may also be needed to explain the 10-fold differential in relative
risk observed by us. Marmot and Smith (43) have pointed out
that Japanese in general have a longer life expectancy than
people in England, and possible explanations for the lower
mortality in Japan could be the effects of different aspects of
Japanese lifestyle. Wynder et al. (13) have suggested previ-
ously that differences in diet, particularly dietary fat, may also
contribute to the differences in lung cancer rates. Gao et al. (4),
using data obtained earlier from a Nagoya hospital population,
reported a protective effect of fruit and vegetable consumption
on risk of lung cancer. Ohno et al. (20) also reported a protec-
tive effect of tea consumption against lung cancer in residents
of Okinawa. All of these factors may be considered as candidate
effect modifiers of smoking-related lung cancer risks in future
studies.
Potential biases from misclassification of ex-smokers as
nonsmokers in some Japanese case-control studies could result
in an underestimate of OR (17). However, it is unlikely that a
substantial nonrandom misclassification would occur in only
one of the two countries unless Japanese ex-smokers and
United States ex-smokers differ greatly in the variety of self-
reports of smoking status. Comparison of the distribution of
smoking prevalence from this study with population statistics
suggests that this is not the case. Because lung cancer in young
patients differs from lung cancer in older patients (44), all of the
OR calculations were adjusted for age in this study. Also,
because smoking behaviors vary by social class (45, 46), edu-
cation level was controlled in the analyses.
Lung cancer cases from hospitals may not be representa-
tive of all of the lung cancer cases in the underlying population.
The smoking prevalence in the control groups was reduced after
excluding hospital patients with diseases related to smoking.
However, the exclusion of smoking related diseases from hos-
pital controls was an important element of the study design and
has been shown to be a successful strategy for reducing selec-
tion bias in case-control studies of tobacco-related diseases in
United States studies (14). In the Japanese study population, all
of the ORs calculated using community controls were higher
than those estimated using hospital controls, but these differ-
ences were small in comparison with United States-Japan dif-
ferences for all of the major dosage variables.
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